Hip Dysplasia, Femoroacetabular Impingement, Osteoarthritis
Conditions
Keywords
Hip, Cam deformity
Brief summary
An abnormally formed hip joint (cam deformity) is a major cause of osteoarthritis (OA). Individuals may not experience any symptoms until OA is severe due to extensive cartilage loss and changes in underlying bone. A series of studies showed that the cam deformity can lead to the development of OA if left untreated, thus strongly suggesting a causal relationship. Currently, the cam deformity that causes pain is surgically removed to relieve the pain and treat the associated cartilage damage. Recent studies have demonstrated that surgical treatment leads to bone and cartilage changes that were related to improved function and reduced pain.
Detailed description
This study will allow the investigators to gain a better understanding of the relationship between cartilage and bone changes. The investigators will examine adult participants in the disease state that require surgical correction and compare to age-matched controls. The investigators will look at the impact of surgical intervention through joint-specific biomarkers of OA, specifically the PET-MRI and blood/urine biomarkers, which will allow them to simultaneously query cartilage and bone activity. The investigators propose that the use of PET-MRI will give more sensitive and hip-specific information about the joint health compared to the blood/urine biomarkers in patients with symptomatic cam morphology. Participants will undergo motion analysis and 3D modeling to help the investigators better understand the disease process during the performance of specific activities and define joint contact mechanics as they relate to the PET-MRI imaging, validating a biomarker for early joint degeneration. This diagnostic tool will be extremely useful for younger individuals with a cam deformity who have not yet developed symptoms. In the future the investigators could use this to detect early degeneration in adolescents to prevent and mitigate development of OA later on. This will also help the investigators develop activity guidelines for people with smaller cam deformities in order to avoid surgery and prevent degeneration.
Interventions
RADIATIONLow-dose CT Scan
Low dose computed tomography, also known as qCT, is sensitive to the mineral content within bone tissue, and can assess bone mineral density, a strong predictor of bone strength and stiffness, which can influence the health of the cartilage. Participants will undergo a low dose CT scan of both hips. Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study.
OTHERBlood/Urine Collection
Collection of blood and urine allows the researchers to look for a biomarker in the blood and urine that might help to predict the evolution of disease/hip osteoarthritis. Identifying a marker in the blood and urine that could be used for early detection of individuals with cam deformity that are at-risk of hip degeneration could greatly improve patient care. Participants in the Cam Group will undergo the blood and urine collection twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo a blood and urine collection once as part of the study.
The purpose of the questionnaires is to assess how much trouble the participant is having with their hip and how it affects their quality of life. Participants in the Cam Group will complete the questionnaires twice; once before surgery and once 2-years post-operative. Participants in the Control Group will complete the questionnaires once as part of the study.
RADIATIONEOS Scan
The EOS® uses a new imaging technique that allows precise measurement of the hip and pelvis geometry and structure. This innovative x-ray technique exposes participants to 2-10 times less radiation than a routine x-ray and can capture multiple images at once. Participants in the Cam Group will undergo the EOS scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study.
RADIATIONPET-MRI
Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that allows physicians to examine bone and cartilage at the molecular level. Participants in the Cam Group will undergo the scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study.
OTHERMotion Analysis
Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising. Participants in the Cam Group will undergo the Motion Analysis session twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the Motion Analysis session once as part of the study.
RADIATION3T MRI
Participants will undergo a 3-Tesla (3T) Magnetic Resonance Imaging (MRI) of both hips. Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study.
Sponsors
Canadian Institutes of Health Research (CIHR)
Ottawa Hospital Research Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Non-randomized, single centre trial with 2 parallel groups
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Skeletally mature patient undergoing cam resection by hip arthroscopy with hip pain longer than 6 months * Absence of arthritis (Tonnis Grade 0 or 1) * Absence of dysplasia (LCEA \> 25°) or overcoverage (LCEA \> 39°) * Alpha angle greater than 55° on multiplanar imaging * Subject is over the age of 18 years old at time of enrollment * Subject is willing and able to complete required study visits and assessments * Subject is willing to sign the approved Informed Consent Form Group 2 Inclusion Criteria: * Normal femoral head neck contour and no evidence of dysplasia * Subject is over the age of 18 years old at time of enrollment * Subject is willing and able to complete required study visits and assessments * Subject is willing to sign the approved Informed Consent Form
Exclusion criteria
* Prior joint replacement surgery in any lower-limb joint due to OA * History of lower-limb joint or back injury in the last year that impairs mobility * Metallic prosthesis * Worked with metal, metal fragments in the eye * Blood transmittable disease(s) * In vivo devices (Aneurysm clip(s), Pacemaker, ICD, Implanted hearing device) * Extreme claustrophobia * Overweight or obese (BMI \> 30) and/or waist circumference \>102cm in men and \>88cm in women * Diagnosis of Parkinson's or uncontrollable tremors * Known history of early OA in the immediate family * Pregnant, Breastfeeding, or planning to get pregnant * Cognitive impairment that prevents accurate completion of patient-reported outcome questionnaires * Patient unable/unwilling to complete all required follow-up visits * Participants who have been exposed to other sources of radiation within the last year (Bringing radiation exposure above annual maximum)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of [18F]-NaF as a biomarker of hip degeneration | 24 months | This study will assess \[18F\]-NaF uptake in PET-MRI as a novel biomarker of hip degeneration. This will be done by evaluating the presence of active bone turnover. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| qCT (Low Dose Computed Tomography) | Within 2 months after recruitment | Used to measure bone mineral density (mass of mineral per volume of bone) in the subchondral bone. Negative scores indicate lower bone density, and positive scores indicate higher. |
| Change in type II collagen telopeptide (CTX-II) | 24 months | Determine the change in urine biomarker levels (type II collagen telopeptide (CTX-II), measured by the ELISA kit, two years after surgical correction of a symptomatic cam deformity. |
| Change in cartilage oligomeric matrix protein (COMP) | 24 months | Determine the change in serum biomarker levels (cartilage oligomeric matrix protein (COMP)), measured by the ELISA kit, two years after surgical correction of a symptomatic cam deformity. |
| Change in C-reactive protein (CRP) | 24 months | Determine the change in serum biomarker levels (C-reactive protein (CRP)), measured by the ELISA kit, two years after surgical correction of a symptomatic cam deformity. |
| Change in N-terminal cross-linking telopeptide of type I collagen (NTX-1) | 24 months | Determine the change in bone turnover plasma biomarker levels (N-terminal cross-linking telopeptide of type I collagen (NTX-1)) two years after surgical correction of a symptomatic cam deformity. |
| Change in carboxy-terminal collagen crosslinks (CTx) | 24 months | Determine the change in bone turnover plasma biomarker levels (carboxy-terminal collagen crosslinks (CTx)), measured by the ELISA kit, two years after surgical correction of a symptomatic cam deformity. |
| Change in PET-MRI (SUV/T1Rho) | 24 months | Determine the change in PET-MRI (SUV/T1Rho) two years after surgical correction of a symptomatic cam deformity to discern disease state. |
| Change in iHot-33 score | 24 months | The International Hip Outcome Tool (iHOT-33 is a questionnaire that evaluates young active patients with early hip disease. The questionnaire is self-administered and assesses across 4 domains: symptoms and functional limitations; sport and recreational activities; job-related concerns; and social, emotional, and lifestyle concerns. Questions are answered by marking a visual analog scale between 2 anchor statements (100-mm scale). The total score is calculated as a simple mean of these responses ranging from 0 to 100, with 100 representing the best possible quality-of-life score. |
| Change in Hip Disability and Osteoarthritis Outcome Score (HOOS) score | 24 months | Hip-specific symptoms and functional impairment will be compared using the Hip Disability and Osteoarthritis Outcome Score (HOOS). This 40-item patient reported outcome tool has 5 categories: pain, symptoms, daily living, quality of life, sports and recreational activities. Each category is scored on 100 points, 0 being the worse outcome and 100 the best outcome. |
| Change in EQ-5D-5L score | 24 months | This questionnaire assesses generic health status. Each question is scored from 1-5, with 1 being no problems and 5 being severe problems. These scores are not aggregated. There are 5 domains: mobility, self-care, usual activities, pain and anxiety. The final question is asking the participant to self score their health that day out of 100 (0 being the worst health and 100 being the best health). |
| Joint Kinematics to predict hip contact forces | 24 months | Retro-reflective markers will be placed on each participant in a laboratory setting. Joint kinematics will be reconstructed from marker trajectories recorded by a 10- camera system (Vicon Vantage & Vicon Vero, Oxford, UK; frequency 200 Hz). Together, with joint kinetics, the investigators will predict hip contact forces. |
| Joint kinetics to predict hip contact forces | 24 months | Retro-reflective markers will be placed on each participant in a laboratory setting. Force platforms will record kinetic data. Together, with joint kinetics, the investigators will predict hip contact forces. |
| Muscle Activity | 24 months | Retro-reflective markers will be placed on each participant in a laboratory setting. Electromyography (EMG) electrodes will be placed over the following muscles: rectus femoris, vastus medialis, vastus lateralis, tensor fascia latea, biceps femoris, semitendinosus, gluteus medius and gluteus maximus. Muscle activity will be measured using EMG signal recorded during maximum voluntary isometric contraction. |
| Change in N-terminal pro-peptide of type I procollagen (PINP) | 24 months | Determine the change in bone turnover serum biomarker levels (N-terminal pro-peptide of type I procollagen (PINP)), measured by the ELISA kit, two years after surgical correction of a symptomatic cam deformity. |
Countries
Canada
Contacts
Primary ContactPaul Beaule, MD, FRCSC
Backup ContactCheryl Kreviazuk, BA
Outcome results
None listed